RT Journal Article
SR Electronic
T1 Factors associated with exacerbations in patients with COPD: NOVELTY study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 2474
DO 10.1183/13993003.congress-2020.2474
VO 56
IS suppl 64
A1 Hana Müllerová
A1 Bo Ding
A1 Eleni Rapsomaniki
A1 Richard Beasley
A1 J Mark Fitzgerald
A1 Tim Harrison
A1 Rod Hughes
A1 Jose Maria Olaguibel
A1 Helen K Reddel
A1 Precil Varghese
A1 Mohsen Sadatsafavi
A1 Christer Janson
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/2474.abstract
AB Background: NOVELTY (NCT02760329) is a global, prospective, observational study of patients with physician-assigned asthma and/or COPD. At baseline, physicians were asked: “During the past 12 months, on how many occasions has your patient experienced an exacerbation of their asthma or COPD beyond the patient's usual day to day variance?”Objective: To describe factors associated with exacerbations in patients with a physician label of COPD (± asthma) enrolled in NOVELTY.Methods: Patients in the NOVELTY baseline cohort were categorised by exacerbation history in the 12 months prior to baseline, with analysis limited to exacerbations that were moderate (managed with oral corticosteroids and/or antibiotics, or an emergency department visit) or severe (required hospital admission).Results: Overall, 5,072 patients had COPD (mean age 66 years, 41% female, mean post-bronchodilator FEV1 64% predicted); 16% reported 1 moderate exacerbation only (Table). Patients with exacerbations were more likely to have concomitant asthma, comorbidities, greater airflow limitation, poorer health status, more missed days of work and more impairment of work due to ill health vs patients without exacerbations.Conclusions: Patients with COPD and a history of exacerbations (even those with only one moderate exacerbation) had a considerably higher disease burden than those without exacerbations, including more work impairment and use of more healthcare resources.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2474.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).